331 related articles for article (PubMed ID: 21619905)
1. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
Barouch DH; Kik SV; Weverling GJ; Dilan R; King SL; Maxfield LF; Clark S; Ng'ang'a D; Brandariz KL; Abbink P; Sinangil F; de Bruyn G; Gray GE; Roux S; Bekker LG; Dilraj A; Kibuuka H; Robb ML; Michael NL; Anzala O; Amornkul PN; Gilmour J; Hural J; Buchbinder SP; Seaman MS; Dolin R; Baden LR; Carville A; Mansfield KG; Pau MG; Goudsmit J
Vaccine; 2011 Jul; 29(32):5203-9. PubMed ID: 21619905
[TBL] [Abstract][Full Text] [Related]
2. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.
Abbink P; Lemckert AA; Ewald BA; Lynch DM; Denholtz M; Smits S; Holterman L; Damen I; Vogels R; Thorner AR; O'Brien KL; Carville A; Mansfield KG; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2007 May; 81(9):4654-63. PubMed ID: 17329340
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
Nanda A; Lynch DM; Goudsmit J; Lemckert AA; Ewald BA; Sumida SM; Truitt DM; Abbink P; Kishko MG; Gorgone DA; Lifton MA; Shen L; Carville A; Mansfield KG; Havenga MJ; Barouch DH
J Virol; 2005 Nov; 79(22):14161-8. PubMed ID: 16254351
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
[TBL] [Abstract][Full Text] [Related]
8. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
[TBL] [Abstract][Full Text] [Related]
9. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.
Penaloza-MacMaster P; Provine NM; Ra J; Borducchi EN; McNally A; Simmons NL; Iampietro MJ; Barouch DH
J Virol; 2013 Feb; 87(3):1373-84. PubMed ID: 23152535
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment.
Privatt SR; Bullard BL; Weaver EA; Wood C; West JT
Vaccine; 2019 Aug; 37(36):5177-5184. PubMed ID: 31378535
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
[TBL] [Abstract][Full Text] [Related]
14. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
15. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
17. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
19. Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.
Sun C; Feng L; Zhang Y; Xiao L; Pan W; Li C; Zhang L; Chen L
J Virol; 2012 Oct; 86(20):11031-42. PubMed ID: 22855499
[TBL] [Abstract][Full Text] [Related]
20. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.
Abbink P; Maxfield LF; Ng'ang'a D; Borducchi EN; Iampietro MJ; Bricault CA; Teigler JE; Blackmore S; Parenteau L; Wagh K; Handley SA; Zhao G; Virgin HW; Korber B; Barouch DH
J Virol; 2015 Feb; 89(3):1512-22. PubMed ID: 25410856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
